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Abstract  
BACKGROUND: High blood cholesterol is part of metabolic syndrome and can be caused by 
medical conditions or bad dietary habits.  
AIM: The aim of the study was to investigate the prevalence of hypercholesterolemia in privies 
diagnosed patients with the severe and very severe stage of COPD, which were stable.  
MATERIAL AND METHODS: We investigated 100 subjects, all of them smokers, with smoking 
status >10 years, stratified into two groups: with severe and very severe stage of the disease. It 
was clinical, randomized, cross-sectional study. Besides demographic parameters and functional 
parameters, body mass index, cholesterol, LDL, and HDL were investigated.  
RESULTS: In the group of patients with very severe COPD were recorded significantly higher 
average values of cholesterol (6.16 ± 1.5 vs. 5.61 ± 1.1, p = 0.039). As independent significant 
factors influencing cholesterol in the group with a very severe COPD were confirmed the age of the 
patients (p = 0.005), LDL (p = 0.004) and HDL (p = 0.002). In the group with severe COPD, only 
LDL was confirmed as an independent significant factor that has an impact on cholesterol (p < 
0.0001).  
CONCLUSION: The results of our survey demonstrated a high level of blood cholesterol and LDL, 
and low level of blood HDL in both investigated group’s patients with COPD. 
 
 
Introduction 
 
Chronic obstructive pulmonary disease 
(COPD) is characterized by minimally reversible or 
irreversible airflow limitation [1]. COPD is increasingly 
considered a multisystem disease characterized by 
both pulmonary and systemic inflammation. 
Pulmonary inflammation is a result of the abnormal 
inflammatory response of the lungs to noxious gasses 
and particles [1, 2]. The main epidemiological risk 
factor is smoking [3, 4]. Metabolic syndrome is defined 
as a complex of interrelated cardiovascular risk. High 
blood cholesterol and high triglycerides are part of 
metabolic syndrome and can be caused by medical 
conditions or bad dietary habits [5, 6].  
Adipose tissue is now recognized not only as 
the main site of storage of excess energy derived from 
food intake but also as an endocrine organ. The 
expansion of adipose tissue produces a number of 
bioactive substances, known as adipocytokines or 
adipokines, which trigger chronic low-grade 
inflammation and interact with a range of processes in 
many different organs. Several inflammatory markers, 
such as TNF-α, PCR, IL-6, IL-8, Fas, Fas-L, 
Lipopolysaccharide Binding Protein have received 
great attention for their role in increased metabolism, 
weight loss, and asthenia although there is still no 
direct evidence for a cause-and-effect relationship 
between them. Systemic inflammation has become 
the primary focus to link COPD and cachexia and to 
explain the development of COPD as a syndrome in 
susceptible subjects [2, 7].  
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Current therapies for COPD have been shown 
to reduce symptoms and exacerbations and to 
improve the quality of life that is a therapeutic priority 
in these patients. However, these drugs have little 
effect on the natural history of the disease 
(progressive decline in lung function and exercise 
tolerance) and do not improve mortality [6]. Some 
authors recommended anti-inflammatory effects of 
statins on both pulmonary and systemic inflammation 
through inhibition of guanosine triphosphates and 
nuclear factor-κB mediated activation of inflammatory 
and matrix remodeling pathways could have 
substantial benefits in patients with COPD due to the 
following: 1) Inhibition of cytokine production (tumor 
necrosis factor-α, interleukin (IL)-6 and IL-8) and 
neutrophil infiltration into the lung; 2) inhibition of the 
fibrotic activity in the lung leading to small airways 
fibrosis and irreversible airflow limitation; 3) 
antioxidant and anti-inflammatory (IL-6 mediated) 
effects on skeletal muscle; 4) reduced inflammatory 
response to pulmonary infection; and 5) inhibition of 
the development (or reversal) of epithelial-
mesenchymal transition, a precursor event to lung 
cancer. Common co-morbidities in COPD are 
cardiovascular diseases and they are associated with 
metabolic syndrome and they increased mortality risk 
in these patients [8-10]. 
A quarter of the world’s adults has metabolic 
syndrome. People with metabolic syndrome are twice 
as likely to die from, and three times as likely to have 
a heart attack or stroke compared with people without 
this syndrome [10]. 
According to the new International Diabetic 
Federation definition, for a person to be defined as 
having the metabolic syndrome must have: central 
obesity plus any two of the following four factors: 
raised triglyceride level, specific treatment for this lipid 
abnormality, reduced HDL cholesterol or specific 
treatment for this lipid abnormality, raised blood 
pressure, or treatment of previously diagnosed 
hypertension, raised fasting plasma glucose, or 
previously diagnosed type 2 diabetes, OGTT is 
strongly recommended but is not necessary to define 
presence of the syndrome [10-12]. In COPD patients, 
metabolic syndrome did not additionally impact 
patients' functional outcomes but did impact the 
prevalence of co-morbidities first of all cardiovascular 
[13-15]. According to dates from some studies high 
level of cholesterol as a part of a metabolic syndrome 
in COPD patients is associated with more serious and 
more frequent exacerbations [16, 17]. 
The aim of the study was to investigate the 
prevalence of hypercholesterinemia [the level of 
cholesterol, HDL (high-density lipoproteins) and LDH 
(low-density lipoproteins)], in previously diagnosed 
COPD patients with severe and very severe stage of 
the disease. 
 
Material and Methods 
 
We investigated 100 subjects with COPD, all 
of them smokers, with smoking status, >10 years. The 
duration of COPD in these patients was more than 9 
years. They were stratified into two groups according 
to Global Initiative for Chronic Obstructive Lung 
Disease (GOLD). Sixty-four with severe stage of the 
disease: 50% > FEV1 ≥ 30%, FEV1/FVC < 0.70 and 
36 subjects with very severe stage of the disease: 
FEV1 < 30%, FEV1/FVC < 0.70. It was clinical, 
randomized, cross-sectional study. Besides 
demographic parameters (age, gender), functional 
parameters, Body mass index (BMI) and the level of 
cholesterol, LDL and HDL were measured in blood. 
 
Statistical analysis 
Statistical analysis of the database was made 
in the program SPSS for Windows 17.0. Testing of the 
distribution of the data was done with Kolmogorov - 
Smirnov and Shapiro-Wilk's test. Categorical variables 
were presented with absolute and relative numbers; 
numeric variables were shown MPC descriptive 
statistics (mean, median, rank values).To test the 
significance of differences between the two COPD 
groups were used parametric and nonparametric 
methods for independent samples (Chi-square test, 
Student's test, Mann-Whitney U test). To determine 
the correlation between cholesterol and certain 
parameters was used Pearson's coefficient of linear 
correlation. Multiple regression analysis was used to 
determine significant independent factors associated 
with cholesterol. Statistically significant values were 
taken at p <0.05. 
 
 
Results 
 
Severe vs. very severe COPD 
The results of our survey show that in male 
patients significantly more likely than in female 
patients were registered very severe COPD (45.45% 
vs. 17.65% p = 0.006) (Table 1). 
Table 1: The prevalence of gender in bout groups of COPD 
patients 
Gender COPD (severe ) 
N = 64 
COPD  (very severe) 
N = 36 
p-value 
Female  n= 34 28 (82.35%) 6 (17.65%) p = 0.006 
Male  n= 66 36 (54.55%) 30 (45.45%) 
p (Chi-square test)  p < 0.01. 
 
Patients with severe and very severe COPD 
were insignificant different average age and BMI (p = 
0.75 and p = 0.14 consequently) (Table 2). 
 Zafirova-Ivanovska et al. Cholesterol in COPD Patients with Severe and Very Severe Stage 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2016 Jun 15; 4(2):277-282.                                                                                                                                                         279 
 
Table 2: The age, body mass index and functional parameters 
in bout groups of patients 
Variable Group Mean ± SD Min - Max p-value 
Age Severe 62.53 ± 11.3 37 – 88  
*p = 0.75 Very severe 
 
61.83 ± 9.1 45 – 80 
BMI (kg/m
2
) 
 
Severe 24.22 ± 5.2 16 – 36  
*p = 0.14 Very severe 
 
25.9 ± 5.9 19.3 – 35 
FVC (L) Severe 1.78 ± 0.5 0.9 - 3.28 *p < 0.01 
 Very severe 
 
1.23 ± 0.4 0.56 -1.89 
FVC (%) 
 
 
FEV1 (L) 
 
 
FEV1 (%) 
 
Severe 56.25 ± 11.2 40 – 88 *p < 0.01 
 
 
*p < 0.01 
 
 
*p < 0.01 
Very severe 
 
Severe 
Very severe 
 
Severe 
Very severe 
 
37.67 ± 12.9 
 
1.02 ± 0.2 
0.67 ± 0.2 
 
40.6 ± 6.8 
23.3±5.1 
 
20 - 67 
 
0.64 -1.58 
0.25 - 0.53 
 
31-50 
11-29 
FEV1/FVC (%) Severe 60.84 ± 6.8 48 – 70 *p < 0.01 
 Very severe 52.61 ± 8.6 36 – 66 
 
p ( Student's t- test). 
 
In the group of patients with very severe 
COPD were recorded significantly higher average 
values of cholesterol (6.16 ± 1.5 vs. 5.61 ± 1.1 p = 
0.039). The values of LDL and HDL were insignificant 
different in the group with severe and very severe 
COPD (p = 0.66 and p = 0.11 respectively) (Table 3).  
Тable 3: The level of cholesterol, LDL, and HDL in patients with 
severe vs. very severe    COPD 
Variable Group Mean ± SD Min - Max Median (IQR) p-value 
 
Cholesterol (mmol/l) 
Severe 5.61 ± 1.1 3.7 – 8.7 5.60 (4.6 – 6.6)  
*p =0.039 Very sever 6.16 ± 1.5 4.3 – 9.6 5.85 (4.9 – 6.7) 
 
LDL (mmol/l) 
Severe 3.10 ± 1.1 1.5 – 5.2 2.75 (2.1 – 3.9)  
**p =0.66 Very severe 3.46 ± 1.7 1.6 – 6.7 3.15 (1.9 – 4.5) 
 
HDL (mmol/l) 
Severe 1.31 ± 0.6 0.4 – 2.2 1.45 (0.75 – 1.8)  
**p =0.11 Very severe 1.08 ± 0.6 0.4 – 2.2 0.85 (0.6 – 1.7) 
    
*, p (Student-s t-test); **, p(Mann-Whitney U test). 
 
Cholesterol 
Male with very severe COPD had significantly 
higher average cholesterol levels than female (5.85 ± 
1.2 vs. 5.29 ± 0.9 p = 0.043). In the group with severe 
COPD, male patients had cholesterol values slightly 
higher than females (p = 0.13) (Table 4). 
Table 4: The average value of cholesterol in female vs male in 
both groups 
COPD 
group 
Gender Descriptive statistics -cholesterol p-value 
mean ± SD min - max median (IQR) 
Severe 
 
Female n=28 5.29 ± 0.9 3.7 – 6.8 5.35 (4.6 – 5.8)  
*p = 0.043 Male n=36 5.85 ± 1.2 4.3 – 8.7 5.65 (4.9 – 6.6) 
Very 
Severe 
Female n=6 5.27 ± 0.8 4.6 – 6.3 4.95 (4.6 – 6.3)  
**p = 0.13 Male n=30 6.34 ± 1.6 4.3 – 9.6 5.90 (5.1 – 7.0) 
*, p ( Student-s t-test);  **, p(Mann-Whitney U test). 
 
In the group with severe COPD, cholesterol 
significantly positively correlated with LDL (r = 0.895, 
p < 0.001), and significantly negatively correlates with 
HDL (r = - 0.667, p <0.001). 
In the group with very severe COPD, 
cholesterol significantly positively correlated with LDL 
(r = 0.895, p <0.001), while significantly negatively 
correlated with the age of patients (r = - 0.458, p = 
0.005) and the values of FVC% (r = - 0.37, p = 0.025) 
and HDL (r = - 0.793, p <0.001) (Table 5).  
Table 5: The correlation of cholesterol with age, functional 
parameters, BMI, cholesterol, LDL, HDL 
Correlation cholesterol/ r  - Pearson 
Severe Very severe 
Age (years) r = - 0.07,  p=0.57 r = - 0.458,  p=0.005  
FVC (L) r =  0.048,  p=0.7 r = - 0.115,  p=0.5 
FVC (%) r =  0.020,  p=0.87 r = - 0.370,  p=0.025 
FEV1 (L) r =  0.037,  p=0.77 r = - 0.115,  p=0.5 
FEV1 (%) r =  - 0.057,  p=0.66 r = - 0.315,  p=0.06 
FEV1/FVC r =  0.070,  p=0.57 r =  0.114,  p=0.4 
BMI (mmol/l) r =  0.038,  p=0.77 r =  0.230,  p=0.18 
LDL (mmol/l) r =  0.895,  p<0.001 r =  0.896,  p<0.001 
HDL (mmol/l) r =  - 0.667,  p<0.001 r =  - 0.793,  p<0.001 
 
Results from Multiple regression analysis 
which investigate the impact of LDL and HDL 
cholesterol in the group with severe COPD, (which 
bivariate analysis proved to be significantly associated 
with cholesterol), only LDL confirmed as an 
independent significant factor that has an impact on 
cholesterol (p < 0.0001). With the increase in LDL by 
1 mmol/l, average values of the cholesterol increase 
of 0.927 (B = 0.927) (Table 6). 
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Figure 1: Correlation - cholesterol vs. age (left) and FVC% (right) in 
the group with a very severe COPD 
 
As independent significant factors influencing 
cholesterol in the group with a very severe COPD 
confirmed the age of the patients (p = 0.005), LDL (p 
= 0.004) and HDL (p = 0.002).With increasing age of 
one year, the average cholesterol was reduced by 
0.044 (B = - 0.044).  
cholesterol = 2,9416 + ,86656 * LDL
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Figure 2: Correlation cholesterol/LDL cholesterol correlated/LDL 
group severe COPD (left) and group very severe COPD (right) 
With increasing values of LDL by 1 mmol/l, 
average values of the cholesterol increase of 0.399 (B 
= 0.399). With increasing values of HDL to 1 mmol/l, 
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average values of cholesterol is reduced by 1.139 (B 
= - 1.139) (Table 7). 
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Figure 3: Correlation cholesterol/HDL cholesterol correlated/HDL 
group severe COPD (left) and group very severe COPD (right) 
 
 
Discussion 
 
Hypercholesterolemia in COPD is considered 
as comorbidity, one of the metabolic syndrome. 
According to some dates severe COPD is associated 
with increased levels of HDL-C, which is partially 
attributable to oral steroid use. HDL-C in this 
population is not associated with reduced risk of 
angiographically proven coronary artery disease [18]. 
Table 6: Multiple Regression analysis of the impact of LDL and 
HDL cholesterol in the group with severe COPD 
                                                               Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95% Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
1           
(Constant) 
2.565 0.463  5.540 0.000 1.639 3.491 
             LDL 0.927 0.087 0.958 10.614 0.000 0.752 1.101 
             HDL 0.147 0.166 0.080 0.882 0.381 -0.186 0.479 
a) Dependent Variable: cholesterol. 
In the Joseph Davaney study from 2014, 
metabolic syndrome was present in 57% of the COPD 
patients and 40% of the healthy subjects. After 
stratification for BMI, presence of metabolic syndrome 
in patients with a BMI ≥ 25 kg/m
2
 was higher than in 
healthy peers. Patients with metabolic syndrome and 
a BMI <25 kg/m
2
 had higher BMI, fat-free mass index, 
and bone mineral density, and a lower 6 MWD than 
the BMI-matched patients without metabolic 
syndrome. In COPD patients with metabolic syndrome 
self-reported comorbidities and medication use were 
higher than in those without [19] 
In our survey in both groups of patients with the 
severe and very severe disease, BMI did not correlate 
significantly with cholesterol. 
Table 7: Multiple regression analysis of the impact of age, FVC, 
LDL, HDL and blood glucose, cholesterol in the group with a 
very severe COPD 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95% Confidence 
Interval for B 
B Std.Error Beta 
Lower 
Bound 
Upper 
Bound 
1           
(Constant) 
8.765 1.537  5.702 0.000 5.634 11.896 
             Age -0.044 0.015 -0.258 -2.979 0.005 -0.075 -0.014 
             LDL 0.399 0.127 0.447 3.150 0.004 0.141 0.657 
             HDL -1.139 0.342 -0.430 -3.332 0.002 -1.836 -0.443 
            
a
. Dependent Variable: cholesterol 
 
Metabolic syndrome did not additionally 
impact patients' functional outcomes but did impact 
the prevalence of comorbidities. Metabolic syndrome 
is a common metabolic disorder defined as a complex 
of interrelated cardiovascular risk factors. Metabolic 
syndrome is age dependent and has been related to 
several other health conditions and an increased 
mortality risk [19]. 
In our survey in the group with very severe 
COPD, cholesterol significantly negatively correlated 
with the age of patients (r = - 0.458, p = 0.005). Men 
with very severe COPD had significantly higher 
average cholesterol levels than women (5.85 ± 1.2 vs. 
5.29 ± 0.9, p = 0.043). In the group with severe 
COPD, male patients had cholesterol values slightly 
higher than females (p = 0.13).  
The prevalence of metabolic syndrome in 
COPD patients compared to healthy subjects has 
been studied scarcely. Marquis and colleagues 
reported an increased prevalence in 38 COPD 
patients compared to 34 healthy subjects (47% vs. 
21%, respectively). A comparable prevalence of 
metabolic syndrome in COPD was reported by Watz 
and colleagues, but no healthy control group was 
included in this study [10, 11, 17]. 
COPD patients with metabolic syndrome are 
physically less active and have increased levels of 
systemic inflammation compared to COPD patients 
without metabolic syndrome. Low-grade systemic 
inflammation has been present in participants with 
moderate to severe airflow obstruction and was 
associated with increased risk of cardiac injury. This 
may in part explain the high rates of cardiovascular 
complications in COPD [19, 20]. 
A number of studies have shown an 
association between COPD and selected CVD end 
points including total cardiac mortality, mortality from 
acute myocardial infarction (AMI), mortality after 
coronary artery bypass graft, and pulmonary 
embolism. Low FEV1 is associated with all-cause 
mortality, CVD mortality, nonfatal and fatal myocardial 
infarction (MI), nonfatal and fatal stroke, and atrial 
fibrillation [21]. 
In our survey in the both groups patients with 
COPD, cholesterol significantly positively correlated 
with LDL (r = 0.895, p <0.001), (r = 0.896, p <0.001) 
and significantly negatively correlates with HDL (r = - 
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0.667, p <0.001); r = - 0.793, p<0.001).  
Osteoporosis is common in advanced COPD, 
potentially impairing quality of life. Increased high-
density lipoprotein cholesterol [HDL-C (high-density 
lipoprotein)] has been observed in COPD and linked 
with osteoporosis in the general population. This 
association has not been previously examined in 
COPD [22]. 
Subjects with COPD who perform some level 
of regular physical activity have a lower risk of both 
COPD admissions and mortality. The 
recommendation that COPD patients are encouraged 
to maintain or increase their levels of regular physical 
activity should be considered in future COPD 
guidelines since it is likely to result in a relevant public 
health benefit [23]. 
Some dates from recent studies suggest that 
exercise can elevate HDL-C. Patients with chronic 
obstructive pulmonary disease (COPD), who are 
usually considered as leading sedentary lifestyles, 
have an increased work of breathing and their 
respiratory muscles may be considered to be under a 
chronic exercise load. Severe COPD is associated 
with increased levels of HDL-C, which is partially 
attributable to oral steroid use. HDL-C in this 
population is not associated with reduced risk of 
angiographically proven coronary artery disease [24, 
25]. 
In conclusion, COPD is considered as a 
systemic disease according to much concomitant 
comorbidity in patients. These comorbidities 
significantly impact on patient outcomes. Evidence for 
this approach has been provided by strong 
associations with increased rates especially with 
cardiovascular diseases, metabolic syndrome, 
anemia, musculoskeletal disease and pulmonary 
malignancies. A number of studies have shown a high 
connectivity between COPD and cardiovascular 
morbidity and mortality and pulmonary embolism. 
Hypercholesterinemia probably is hugely responsible 
for those events. The results of our survey show a 
high level of blood cholesterol and LDL, and low level 
of blood HDL in both investigated group’s patients 
with COPD. Patients with very severe COPD have 
significantly higher average values of cholesterol (6.16 
± 1.5 vs. 5.61 ± 1.1, p = 0.039). The values of LDL 
and HDL were insignificant different in the group with 
severe and very severe COPD (p = 0.66 and p = 0.11 
respectively). 
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